Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371092 | 0.90 | ESR2 (0.34) | DGAT1ESR2SOAT1CYP2C9OPRL1 | |
| SCHEMBL12371018 | 0.80 | GRM2 (0.35) | GRM2P2RY14 | |
| SCHEMBL12370962 | 0.79 | GRM2 (0.34) | GRM2P2RY14 | |
| SCHEMBL16104424 | 0.78 | CYP2C9 (0.42) | DGAT1ESR2CYP2C9 | |
| SCHEMBL3437362 | 0.78 | CYP2C9 (0.50) | DGAT1ESR2SOAT1CYP2C9GRIN2B | |
| SCHEMBL7756528 | 0.78 | CYP2C9 (0.50) | DGAT1ESR2SOAT1CYP2C9GRIN2B | |
| SCHEMBL29432469 | 0.78 | CYP2C9 (0.50) | DGAT1ESR2SOAT1CYP2C9GRIN2B | |
| SCHEMBL3437348 | 0.77 | CYP2C9 (0.41) | DGAT1ESR2CYP2C9P2RY14 | |
| SCHEMBL29432456 | 0.77 | CYP2C9 (0.41) | DGAT1ESR2CYP2C9P2RY14 | |
| SCHEMBL7756531 | 0.77 | CYP2C9 (0.41) | DGAT1ESR2CYP2C9P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | OGDH, OXGR1, OXER1 | GRM2 1003/4885DGAT1 2078/4885ESR2 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.